← Leaderboards
Feng-Chun Yang
University Of Texas Hlth Science Center
$5,883,606
Attributed
$10,237,773
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,237,773 · 9
By mechanism
R01$9,256,047 · 5
T32$606,758 · 2
R21$369,968 · 1
R13$5,000 · 1
Top collaborators
- Mingjiang Xu17 shared
- David W. Clapp5 shared
- Helmut Hanenberg5 shared
- Pei Wang2 shared
- Rebecca J Chan1 shared
- Maria Eugenia Figueroa1 shared
Others in their field
Top investigators on “Hematopoietic”
- Mary M Horowitz · Medical College Of Wisconsin$225,743,807
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$75,636,774
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$46,290,940
- Megan Sykes · Columbia University Health Sciences$41,013,082
- David T Scadden · Massachusetts General Hospital$37,607,985
- Bruce R. Blazar · University Of Minnesota$36,961,789
Research focus
HematopoieticCellsGenesMediatingMyeloproliferative DiseaseIn VivoHematopoietic Stem CellsMouse ModelHematopoiesisMolecularGene ExpressionGenome-WidePathogenesisRegulationComplexBehaviorProteinsMalignant NeoplasmsMemberIn VitroBindingTransgene ExpressionC-TerminalChromatin
Grant awards (36)
Cancer Biology Training Program$224,473
T32 · FY2025 · CA · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$473,611
R01 · FY2024 · CA · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology$310,000
R01 · FY2024 · HL · contact PI
Cancer Biology Training Program$243,603
T32 · FY2024 · CA · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology$310,000
R01 · FY2023 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$232,957
R01 · FY2023 · CA · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology$79,143
R01 · FY2023 · HL · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology$64,534
R01 · FY2023 · HL · contact PI
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$561,228
R01 · FY2022 · HL
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology$310,000
R01 · FY2022 · HL · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology.$29,481
R01 · FY2022 · HL · contact PI
Role of BRD4 in Normal Hematopoiesis and Hematopoietic Stem Cell Biology_$24,611
R01 · FY2022 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$1
R01 · FY2022 · CA · contact PI
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$558,814
R01 · FY2021 · HL
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$366,542
R01 · FY2021 · CA · contact PI
Role of PHF6 in Normal Hematopoiesis and hematopoietic stem cell biology$309,667
R01 · FY2021 · HL · contact PI
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$557,606
R01 · FY2020 · HL
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$365,750
R01 · FY2020 · CA · contact PI
Role of PHF6 in Normal Hematopoiesis and hematopoietic stem cell biology$308,000
R01 · FY2020 · HL · contact PI
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$555,796
R01 · FY2019 · HL
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$364,563
R01 · FY2019 · CA · contact PI
Role of PHF6 in Normal Hematopoiesis and hematopoietic stem cell biology$307,000
R01 · FY2019 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2018 · CA · contact PI
Cancer Epigenetics Training Program$138,682
T32 · FY2018 · CA · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2017 · CA · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2016 · CA · contact PI
Genetic Therapy for Fanconi Anemia$319,550
R01 · FY2015 · CA
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2015 · CA · contact PI
No-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutations$200,318
R21 · FY2015 · CA · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$323,700
R01 · FY2014 · CA · contact PI
Genetic Therapy for Fanconi Anemia$309,964
R01 · FY2014 · CA
No-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutations$169,650
R21 · FY2014 · CA · contact PI
Genetic Therapy for Fanconi Anemia$300,377
R01 · FY2013 · CA
Genetic Therapy for Fanconi Anemia$319,550
R01 · FY2012 · CA
Midwest Blood Club Symposium, 2012$5,000
R13 · FY2012 · HL
Genetic Therapy for Fanconi Anemia$319,550
R01 · FY2011 · CA